MCID: HYP073
MIFTS: 41

Hypersensitivity Reaction Type Iv Disease

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Hypersensitivity Reaction Type Iv Disease

MalaCards integrated aliases for Hypersensitivity Reaction Type Iv Disease:

Name: Hypersensitivity Reaction Type Iv Disease 12 14
Immunoproliferative Disorders 42 69
Immunoproliferative Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2916
ICD10 33 C88.9 C88
MeSH 42 D007160
UMLS 69 C0021070

Summaries for Hypersensitivity Reaction Type Iv Disease

MalaCards based summary : Hypersensitivity Reaction Type Iv Disease, also known as immunoproliferative disorders, is related to sarcoidosis 1 and autoimmune lymphoproliferative syndrome. An important gene associated with Hypersensitivity Reaction Type Iv Disease is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Fenofibrate and Rosiglitazone have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and cellular

Related Diseases for Hypersensitivity Reaction Type Iv Disease

Diseases in the Hypersensitivity Reaction Disease family:

Hypersensitivity Reaction Type Iii Disease Hypersensitivity Reaction Type Iv Disease
Hypersensitivity Reaction Type Ii Disease

Diseases related to Hypersensitivity Reaction Type Iv Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 249)
id Related Disease Score Top Affiliating Genes
1 sarcoidosis 1 31.2 CD40LG CD79A IFNG TNF
2 autoimmune lymphoproliferative syndrome 11.0
3 heavy chain disease 11.0
4 cryoglobulinemia 11.0
5 hypercalcemic sarcoidosis 10.9 ACE LYZ
6 alcoholic neuropathy 10.9 CD40LG CD79A
7 calloso-genital dysplasia 10.9 CD40LG CD79A
8 median arcuate ligament syndrome 10.9 CD40LG SMUG1
9 variola major 10.9 CD40LG CD79A
10 mu chain disease 10.9 CD40LG CD79A
11 rabies 10.9 CD40LG CD79A
12 familial retinoblastoma 10.9 CD40LG CD79A
13 anti-basement membrane glomerulonephritis 10.9 CD40LG CD79A
14 microinvasive cervical squamous cell carcinoma 10.9 CD40LG CD79A
15 fetal erythroblastosis 10.9 CD40LG CD79A
16 spinal canal and spinal cord meningioma 10.9 CD40LG CD79A
17 trichostrongyloidiasis 10.9 CD40LG CD79A
18 leukodystrophy 10.9 CD40LG CD79A
19 retinal microaneurysm 10.8 CD40LG CD79A
20 heart septal defect 10.8 CD40LG CD79A
21 cryptorchidism arachnodactyly mental retardation 10.8 CD40LG CD79A
22 unilateral hypoactive labyrinth 10.8 CD79A LYZ
23 anthracosis 10.8 ACE SMUG1
24 acute kidney tubular necrosis 10.8 CD40LG CD79A
25 secretory meningioma 10.8 CD40LG CD79A
26 hodgkin's lymphoma, nodular sclerosis 10.8 CD40LG CD79A
27 imperforate oropharynx-costo vetebral anomalies 10.8 CD40LG CD79A
28 malignant otitis externa 10.8 CD40LG CD79A
29 transient hypogammaglobulinemia 10.8 CD40LG CD79A
30 generalized atherosclerosis 10.7 CD40LG CD79A MYOM2
31 acute hemorrhagic encephalitis 10.7 CD40LG CD79A MYOM2
32 diabetic peripheral angiopathy 10.7 ACE CD40LG LYZ
33 arteriosclerosis 10.7 CD40LG CD79A MYOM2
34 autoimmune disease of cardiovascular system 10.7 CD40LG CD79A TLR9
35 cryptogenic late-onset epileptic spasms 10.7 ACE TNF
36 angiomatous meningioma 10.7 CD40LG CD79A MYOM2
37 late yaws 10.7 CD40LG CD79A TLR9
38 ovarian squamous cell carcinoma 10.7 SMUG1 TNFRSF1B
39 brain germinoma 10.7 CD40LG CD79A TLR9
40 rheumatic heart disease 10.7 CD40LG CD79A SMUG1
41 villoglandular endometrial endometrioid adenocarcinoma 10.7 CD40LG CD79A SMUG1
42 immune-complex glomerulonephritis 10.7 CD40LG CD79A LYZ
43 prostate neuroendocrine neoplasm 10.7 ACE CD40LG CD79A
44 postinflammatory pulmonary fibrosis 10.7 CD40LG CD79A LYZ
45 glycogen storage disease viii 10.7 CD40LG CD79A LYZ
46 benign epilepsy with centrotemporal spikes 10.7 CD40LG CD79A
47 pericardium disease 10.7 ACE MYOM2 TNF
48 ileocolitis 10.7 CD40LG CD79A TNF
49 dermatomycosis 10.7 CD40LG CD79A TNF
50 bladder diverticulum 10.7 CD40LG CD79A TNF

Graphical network of the top 20 diseases related to Hypersensitivity Reaction Type Iv Disease:



Diseases related to Hypersensitivity Reaction Type Iv Disease

Symptoms & Phenotypes for Hypersensitivity Reaction Type Iv Disease

GenomeRNAi Phenotypes related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 TNFRSF1B ACE CD40LG FAS IL2 NOD2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ACE CD40LG FAS IL2 NOD2 TNF

MGI Mouse Phenotypes related to Hypersensitivity Reaction Type Iv Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 SMUG1 TLR9 TNF TNFRSF1B CD40LG CD79A
2 hematopoietic system MP:0005397 10.15 IFNG IL1RN IL2 LYZ NOD2 TLR9
3 homeostasis/metabolism MP:0005376 10.13 NOD2 SMUG1 TLR9 TNF TNFRSF1B ACE
4 immune system MP:0005387 10.03 ACE CD40LG CD79A FAS IFNG IL1RN
5 digestive/alimentary MP:0005381 10.01 FAS IFNG IL2 LYZ NOD2 TLR9
6 liver/biliary system MP:0005370 9.76 ACE CD79A FAS IFNG IL2 LYZ
7 neoplasm MP:0002006 9.61 ACE CD79A FAS IFNG IL2 LYZ
8 renal/urinary system MP:0005367 9.23 FAS IFNG LYZ TLR9 TNFRSF1B ACE

Drugs & Therapeutics for Hypersensitivity Reaction Type Iv Disease

Drugs for Hypersensitivity Reaction Type Iv Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fenofibrate Approved Phase 4 49562-28-9 3339
2
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
3 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
4
Fluticasone Phase 4 90566-53-3, 80474-14-2 62924 22833648
5 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
6 Hypoglycemic Agents Phase 4,Phase 2
7 Hypolipidemic Agents Phase 4
8 Lipid Regulating Agents Phase 4
9
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
10
Gemcitabine Approved Phase 3 95058-81-4 60750
11
Pancrelipase Approved Phase 3 53608-75-6
12
Dobutamine Approved Phase 3 34368-04-2 36811
13 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
14 Anti-Infective Agents Phase 3,Phase 2,Phase 1
15 Antimetabolites, Antineoplastic Phase 3
16 Antiviral Agents Phase 3,Phase 2,Phase 1
17 pancreatin Phase 3
18 Autonomic Agents Phase 3,Phase 1,Phase 2
19 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
20 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
21 Adrenergic Agents Phase 3
22 Adrenergic Agonists Phase 3
23 Adrenergic beta-Agonists Phase 3
24 Protective Agents Phase 3
25
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
26
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
27
Delavirdine Approved Phase 2 136817-59-9 5625
28
Didanosine Approved Phase 2 69655-05-6 50599
29
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
30
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
31
Saquinavir Approved, Investigational Phase 2 127779-20-8 60787
32
Stavudine Approved, Investigational Phase 2 3056-17-5 18283
33
Zidovudine Approved Phase 2,Phase 1 30516-87-1 35370
34
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
35
Aluminum hydroxide Approved Phase 2,Phase 1 21645-51-2
36
Aluminum sulfate Approved Phase 2,Phase 1 10043-01-3
37
Acetaminophen Approved Phase 1, Phase 2 103-90-2 1983
38
Diphenhydramine Approved Phase 1, Phase 2 58-73-1, 147-24-0 3100
39
Histamine Approved, Investigational Phase 1, Phase 2 75614-87-8, 51-45-6 774
40
Promethazine Approved Phase 1, Phase 2 60-87-7 4927
41
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
42
Tadalafil Approved, Investigational Phase 1, Phase 2 171596-29-5 110635
43
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754 657311
44
Mifepristone Approved, Investigational Phase 1, Phase 2 84371-65-3 55245
45
Abatacept Approved Phase 2 332348-12-6 10237
46
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
47
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
48
Peginterferon alfa-2b Approved Phase 1, Phase 2 99210-65-8, 215647-85-1
49
Valproic Acid Approved, Investigational Phase 1, Phase 2 99-66-1 3121
50
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 89)

id Name Status NCT ID Phase Drugs
1 A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis Completed NCT01270958 Phase 4 Avamys aqueous nasal spray 110mcg
2 Non-Specific Effects of Standard Titre Measles Vaccination Completed NCT00168662 Phase 4
3 Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease Not yet recruiting NCT03021941 Phase 4 Elelyso 60 units/kg
4 Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL) Terminated NCT00819910 Phase 4 Rosiglitazone;Placebo (Rosiglitazone);Placebo (Fenofibrate);Fenofibrate
5 A Multi-center Study of Spherule-Derived Coccidioidin Completed NCT00690092 Phase 3
6 Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00425360 Phase 3 capecitabine;gemcitabine hydrochloride
7 Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142 Active, not recruiting NCT02552238 Phase 3 Lumason
8 Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141 Active, not recruiting NCT02522481 Phase 3 Lumason
9 Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer Unknown status NCT00847171 Phase 2 cyclophosphamide
10 Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315 Completed NCT00000891 Phase 2 Ritonavir;Saquinavir;Delavirdine mesylate;Lamivudine;Stavudine;Zidovudine;Didanosine
11 A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy Completed NCT00000820 Phase 2 Aldesleukin
12 A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults Completed NCT00001031 Phase 2
13 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Completed NCT00923910 Phase 1, Phase 2 WT1 Peptide-Pulsed Dendritic Cells;Donor Lymphocytes;IL-4;KLH;WT1 Peptides;Endotoxin;Diphenhydramine;Acetaminophen
14 Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma Completed NCT00436930 Phase 2
15 Immune Responses to BCG Vaccination in Malawi and the UK Completed NCT00241657 Phase 2
16 Stem Cells in Rapidly Evolving Active Multiple Sclerosis Completed NCT01606215 Phase 1, Phase 2 Mesenchymal stem cells;Placebo
17 Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen Completed NCT00633009 Phase 2
18 Activated White Blood Cells in Treating Patients Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Stage II or Stage III Multiple Myeloma Completed NCT00566098 Phase 1, Phase 2 melphalan
19 Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes Completed NCT02127047 Phase 2 Sitagliptin;Exercise
20 PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC Recruiting NCT02544880 Phase 1, Phase 2 Tadalafil
21 Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients. Recruiting NCT02718391 Phase 2
22 Treatment of Patients With Progressive and/or Refractory Solid Malignancies Recruiting NCT02224599 Phase 1, Phase 2
23 Consolidation Therapy in Patients With Metastatic Solid Malignancies Recruiting NCT02705703 Phase 1, Phase 2
24 Tocilizumab (TCZ) in New-onset Type 1 Diabetes Recruiting NCT02293837 Phase 2 Tocilizumab (TCZ);Placebo
25 Mifepristone for Metabolic Syndrome Recruiting NCT01419535 Phase 1, Phase 2 Mifepristone
26 CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Recruiting NCT01773707 Phase 2 CTLA4-Ig (Abatacept);Placebo
27 Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Active, not recruiting NCT02019524 Phase 1, Phase 2
28 Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas Active, not recruiting NCT00766753 Phase 1, Phase 2
29 A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer Active, not recruiting NCT01616303 Phase 2 Carboplatin & paclitaxel
30 Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients Active, not recruiting NCT02692976 Phase 2
31 Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer. Active, not recruiting NCT02919644 Phase 2 IL2
32 A Phase II Randomised Double-blind, Placebo-controlled Study of Revacept in Patients With Stable Coronary Artery Disease Not yet recruiting NCT03312855 Phase 2 Revacept 80 mg;Revacept 160 mg;Placebo
33 Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients Terminated NCT00929019 Phase 1, Phase 2
34 A Study of Anti-CTLA4 Antibody in People With Advanced Synovial Sarcoma Terminated NCT00140855 Phase 2 Anti-CTLA4 (monoclonal antibody MDX-010)
35 Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma Terminated NCT00854581 Phase 1, Phase 2 Valproic Acid;Zidovudine
36 Vaccine Therapy in Treating Patients With Kidney Cancer Terminated NCT00014131 Phase 1, Phase 2
37 Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck Terminated NCT01192815 Phase 2 erlotinib hydrochloride
38 A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells Completed NCT00000667 Phase 1
39 A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen Completed NCT00000782 Phase 1
40 A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals Completed NCT00001042 Phase 1
41 A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults. Completed NCT00001044 Phase 1
42 Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer Completed NCT00850785 Phase 1
43 Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD) Completed NCT01910662 Phase 1
44 Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis Completed NCT01268358 Phase 1 Lamazym
45 Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer Completed NCT00093834 Phase 1 cyclophosphamide;doxorubicin hydrochloride
46 Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route Completed NCT00614731 Phase 1
47 Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis Completed NCT03089775 Phase 1 BBI-2000;Vehicle
48 Tetravalent Chimeric Dengue Vaccine Trial Completed NCT01110551 Phase 1 Placebo (SC);Placebo (ID)
49 NatrOVA Photoallergy Study - NatrOVA Creme Rinse in Healthy Volunteers Completed NCT00605956 Phase 1 NatrOVA Creme Rinse - 1%;NatrOVA Creme Rinse Vehicle Only;Blank Patch
50 NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Completed NCT00199849 Phase 1

Search NIH Clinical Center for Hypersensitivity Reaction Type Iv Disease

Cochrane evidence based reviews: immunoproliferative disorders

Genetic Tests for Hypersensitivity Reaction Type Iv Disease

Anatomical Context for Hypersensitivity Reaction Type Iv Disease

MalaCards organs/tissues related to Hypersensitivity Reaction Type Iv Disease:

39
Skin, Testes, T Cells, Brain, Monocytes, Myeloid, Eye

Publications for Hypersensitivity Reaction Type Iv Disease

Variations for Hypersensitivity Reaction Type Iv Disease

Expression for Hypersensitivity Reaction Type Iv Disease

Search GEO for disease gene expression data for Hypersensitivity Reaction Type Iv Disease.

Pathways for Hypersensitivity Reaction Type Iv Disease

Pathways related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show all 34)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 BTNL2 CASP10 CD40LG CD79A IFNG IL1RN
2
Show member pathways
13.31 CD40LG IFNG IL1RN IL2 NOD2 TNF
3
Show member pathways
12.8 CD40LG FAS IFNG IL2 TNF
4
Show member pathways
12.8 ACE FAS IFNG IL2 TLR9 TNF
5
Show member pathways
12.74 FAS IFNG IL2 TLR9 TNF
6
Show member pathways
12.64 CD40LG IL2 TLR9 TNF TNFRSF1B
7
Show member pathways
12.6 CD40LG FAS IFNG TNF TNFRSF1B
8
Show member pathways
12.56 CD40LG CD79A IFNG IL2 TNF TNFRSF1B
9
Show member pathways
12.54 CASP10 CD40LG FAS TLR9 TNF TNFRSF1B
10
Show member pathways
12.38 CD40LG FAS IFNG IL2 TNF
11
Show member pathways
12.28 CASP10 FAS TNF TNFRSF1B
12
Show member pathways
12.14 FAS IFNG TLR9 TNF
13 12.11 CASP10 IFNG NOD2 TLR9 TNF
14 11.95 CD79A IFNG IL2 TNF
15
Show member pathways
11.89 IFNG IL2 TLR9 TNF
16 11.77 CD40LG CD79A FAS IFNG IL1RN IL2
17 11.75 CASP10 FAS NOD2 TNF TNFRSF1B
18
Show member pathways
11.74 CD40LG FAS TNF TNFRSF1B
19 11.73 IFNG IL2 TNF
20
Show member pathways
11.69 CD40LG TNF TNFRSF1B
21
Show member pathways
11.68 CD40LG IFNG IL2 TNF
22 11.66 CD40LG TLR9 TNF
23 11.66 IFNG IL2 TLR9 TNF
24
Show member pathways
11.59 IFNG IL2 TNF
25
Show member pathways
11.53 CD40LG IFNG IL2 TNF
26
Show member pathways
11.5 IFNG TNF TNFRSF1B
27 11.48 IL1RN TNF TNFRSF1B
28 11.46 IFNG IL2 TNF
29 11.41 FAS IFNG IL2 TNF
30 11.36 CD40LG IFNG TLR9 TNF
31 11.23 IFNG IL2 TNF
32 11.1 FAS IFNG TLR9 TNF
33 10.98 CD40LG IFNG IL2 TNFRSF1B
34
Show member pathways
10.96 FAS IFNG IL2 TNF TNFRSF1B

GO Terms for Hypersensitivity Reaction Type Iv Disease

Cellular components related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.92 ACE CD40LG IFNG IL1RN IL2 LYZ
2 extracellular region GO:0005576 9.65 ACE CD40LG FAS IFNG IL1RN IL2
3 membrane raft GO:0045121 9.56 CD79A FAS TNF TNFRSF1B
4 CD95 death-inducing signaling complex GO:0031265 9.16 CASP10 FAS
5 external side of plasma membrane GO:0009897 9.1 ACE CD40LG CD79A FAS IFNG TNF

Biological processes related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show all 28)
id Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.94 CASP10 CD79A IFNG TNFRSF1B
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.88 CASP10 NOD2 TLR9 TNF
3 positive regulation of protein phosphorylation GO:0001934 9.88 FAS IFNG IL2 TNF
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 CD40LG NOD2 TLR9 TNF
5 tumor necrosis factor-mediated signaling pathway GO:0033209 9.84 CD40LG FAS TNF TNFRSF1B
6 defense response to bacterium GO:0042742 9.8 IFNG LYZ NOD2 TLR9 TNF
7 positive regulation of JNK cascade GO:0046330 9.79 NOD2 TLR9 TNF
8 response to glucocorticoid GO:0051384 9.78 FAS IL1RN TNF
9 positive regulation of tumor necrosis factor production GO:0032760 9.77 IFNG NOD2 TLR9
10 positive regulation of interleukin-6 production GO:0032755 9.74 NOD2 TLR9 TNF
11 immune response GO:0006955 9.7 CD40LG FAS IFNG IL1RN IL2 TNF
12 positive regulation of interleukin-8 production GO:0032757 9.67 NOD2 TLR9 TNF
13 apoptotic signaling pathway GO:0097190 9.67 CASP10 FAS TNF TNFRSF1B
14 positive regulation of interleukin-17 production GO:0032740 9.63 IL2 NOD2
15 maintenance of gastrointestinal epithelium GO:0030277 9.63 NOD2 TLR9
16 positive regulation of interleukin-12 production GO:0032735 9.63 CD40LG IFNG TLR9
17 positive regulation of isotype switching to IgG isotypes GO:0048304 9.62 IFNG IL2
18 positive regulation of chemokine biosynthetic process GO:0045080 9.62 IFNG TNF
19 positive regulation of interleukin-10 production GO:0032733 9.61 CD40LG NOD2 TLR9
20 necroptotic signaling pathway GO:0097527 9.6 FAS TNF
21 regulation of immunoglobulin secretion GO:0051023 9.56 CD40LG TNF
22 positive regulation of T cell proliferation GO:0042102 9.56 BTNL2 CD40LG IFNG IL2
23 inflammatory cell apoptotic process GO:0006925 9.52 FAS IFNG
24 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 IFNG TNF
25 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.5 IFNG TNF TNFRSF1B
26 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 IFNG TNF
27 extrinsic apoptotic signaling pathway GO:0097191 9.26 FAS IFNG TNF TNFRSF1B
28 inflammatory response GO:0006954 9.17 CD40LG FAS IL1RN LYZ TLR9 TNF

Molecular functions related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 CD40LG IFNG IL1RN IL2 TNF
2 peptidyl-dipeptidase activity GO:0008241 8.96 ACE ENSG00000264813

Sources for Hypersensitivity Reaction Type Iv Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....